Pachypodol

Pachypodol is an orally active methoxyflavonoid compound. Pachypodol activates the ERK-dependent Nrf2 pathway and inhibits Apoptosis. Pachypodol exhibits activities such as antioxidant, cytoprotective, anti-inflammatory effects. Pachypodol improves cognition. Pachypodol exerts protective effects against cardiac and liver damage. Pachypodol has anticancer activity against colon cancer^{[1][2][3][4][5]}. In Vitro:Pachypodol (3-30 μM; 1-12 h) significantly prevents oxidative stress-induced cell death in HepG2 cells in a concentration-dependent manner^[1].
Pachypodol (0-30 μM; 24 h) inhibits the growth of CaCo-2 colon cancer cell line, with an IC₅₀ value of 185.6 μM^[2].
In Vivo:Pachypodol (10 mg/kg; 30 days) attenuates Arsenic triggered cardiac damage in rats via rectifying oxidative stress, inflammation, apoptosis and histopathological alterations^[3].
Pachypodol (10-30 mg/kg; i.v.; 30 min before isoflurane exposure) reduces neuronal apoptosis and oxidative stress in Isoflurane (HY-A0134)-induced neuron-injured rats by regulating the JNK/ERK pathway, and also ameliorates cognitive function and neurological scores^[4].
Pachypodol (20 mg/kg; p.o.; once a day; 7-28 days) significantly alleviates Cisplatin (HY-17394)-induced hepatic impairment in albino rats by inhibiting oxidative stress, inflammation, and apoptosis, and mitigates histopathological liver damage^[5].